Headlines
Headlines

Greg Kunst Appointed CEO of Aurion Biotech

Seattle & Boston, June 8 2021 (Business Wire) — Greg Kunst has been named chief executive officer of newly-launched Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases. The company’s first candidate is a cell therapy for the treatment of corneal endothelial disease, which affects millions of people worldwide, with symptoms that include blurred vision, glare, discomfort and pain. Invented by world-renowned ophthalmic surgeon and research scientist Professor Shigeru Kinoshita and his distinguished colleagues at Kyoto Prefecture University of Medicine (KPUM) in Japan, corneal endothelial cell therapy has demonstrated long-term efficacy in Phase 2 and Phase 3 studies in Japan. More

Read More »
Headlines
Headlines

Monogram Health Closes $160M Series B Funding to Fuel Acceleration of Next Generation Kidney Care Model

Nashville, TN., June 8, 2021 (PRNewswire) — Monogram Health, a benefit management and care delivery company transforming care for individuals with chronic kidney and end-stage renal disease, today announced that it has closed a $160 million Series B funding round led by TPG Capital, the private equity platform of global alternative asset firm TPG. The funding round also includes existing investors Frist Cressey Ventures and Norwest Venture Partners, as well as Humana Inc. and other notable national and regional strategic investors. More

Read More »
Headlines
Headlines

venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences

San Francisco, CA June 3 2021 (Business Wire) — venBio today announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad range of institutional investors comprising corporate pensions, financial institutions, university endowments and foundations, family offices and funds-of-funds. More

Read More »
Headlines
Headlines

MorphImmune, Inc. Appoints Ronald Martell as President and CEO

San Francisco, June 2, 2021 (PRNewswire) — MorphImmune, Inc., a private platform company that is advancing a highly specific targeting technology that uses a ligand-linked payload to reprogram the immune system, announced the appointment of Ronald Martell as the company’s President and CEO effective April 12, 2021. More

Read More »
Headlines
Headlines

Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients

Danvers, MA, June 1 2021, (Business Wire) — Abiomed (NASDAQ: ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed’s product portfolio to expand options for patients with acute decompensated heart failure (ADHF). The preCARDIA system is uniquely designed to rapidly treat ADHF-related volume overload by effectively reducing cardiac filling pressures and promoting decongestion to improve overall cardiac and renal function. More

Read More »
Headlines
Headlines

Verseau Therapeutics Appoints John Edwards as Chief Executive Officer

Bedford, MA, May 26, 2021(Business Wire) — Verseau Therapeutics, Inc. today announced the appointment of John Edwards as Chief Executive Officer. John brings over 30 years of biopharmaceutical leadership experience and has been involved in the discovery, development or global commercialization of 10 FDA-approved biologics and eight biotech companies with successful exits. More

Read More »
Headlines
Headlines

Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases

Chicago & Dublin & Trevose, PA (Business Wire) — Xeris Pharmaceuticals, Inc. (“Xeris”) (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, and Strongbridge Biopharma plc (“Strongbridge”) (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that they have entered into a definitive agreement under which Xeris will acquire Strongbridge for stock and contingent value rights (“CVRs”). More

Read More »
Headlines
Headlines

Axonics closes $201.3M offering

Irvine, CA, May 12 2021 (Business Wire) — Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 4,600,000 shares of common stock at the public offering price of $32.50 per share, which includes the shares purchased pursuant to the exercise in full of the underwriters’ option to purchase up to an additional 600,000 shares of its common stock. More

Read More »
Headlines
Headlines

Caris Life Sciences Raises $830 Million in Growth Equity Capital to Continue to Expand its Precision Medicine Platform

Irving, TX, May 11, 2021 (PRNewswire) — Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence (AI) focused on fulfilling the promise of precision medicine, announced an $830 million growth equity round at a post-money valuation of $7.83 billion. With this investment, Caris has raised approximately $1.3 billion in external financing since 2018. This financing represents one of the largest capital raises in precision medicine and includes a diverse syndicate of leading investors. More

Read More »
Headlines
Headlines

Ginkgo Bioworks to Become a Public Company

oston and Los Angeles, May 11, 2021 (PRNewswire) — Ginkgo Bioworks, Inc. (“Ginkgo”) and Soaring Eagle Acquisition Corp. (Nasdaq: SRNG) (“Soaring Eagle”), a publicly traded special purpose acquisition company, have agreed to a business combination that will result in Ginkgo becoming a publicly-listed company. More

Read More »
Headlines
Headlines

WCG Acquires The Avoca Group

Princeton, N.J., May 11, 2021 (PRNewswire) — WCG™, a leading provider of clinical trial solutions, announced its acquisition of The Avoca Group, a life sciences consulting firm supporting biopharma, biotech, CROs and clinical service providers, which is dedicated to improving efficiency, increasing process quality, and mitigating risk in clinical trials. With the addition of The Avoca Group, WCG expands its portfolio of solutions focused on improving patient access to needed therapies by reducing the time needed and expenses incurred in clinical trials, ensuring regulatory compliance, and improving quality management. More

Read More »